Price$309.53-3.27 (-1.05%)
01:30 PM07:45 PM
News · 26 weeks44-50%
2025-10-262026-04-19
Mix3390d
- Insider17(52%)
- SEC Filings7(21%)
- Earnings4(12%)
- Other3(9%)
- Dividends1(3%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form 10-Q filed by West Pharmaceutical Services Inc.10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- SECWest Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- PRWest Reports First-Quarter 2026 ResultsStrong Start to the Year and Raising Full-Year Revenue and EPS guidanceEXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026. First-Quarter Summary (comparisons to prior-year period)Net sales of $844.9 million increased 21.0%; organic growth was 15.3%.Diluted earnings per share ("EPS") of $1.92 increased 56.1%.Adjusted-diluted EPS of $2.13 increased 46.9%.Operating cash flow was $89.9 million. C
- PRWest to Host First-Quarter 2026 Conference CallEXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2026 financial results before the market opens on Thursday, April 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone partic
- INSIDERSEC Form 4 filed by Haugen Janet Brutschea4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- PRWest Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and ObesityEXTON, Pa., March 31, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West's contract services and is designed to meet growing global demands of its customers' high-volume treatments, including diabetes and obesity. "West is honored to continue supporting our customers in providing reliable, high-quality drug delivery solutions and security
- SECAmendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.SCHEDULE 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
- SECSEC Form DEFA14A filed by West Pharmaceutical Services Inc.DEFA14A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- SECSEC Form DEF 14A filed by West Pharmaceutical Services Inc.DEF 14A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- SECWest Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- PREric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc.EXTON, Pa., March 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026. In parallel with today's announcement, the Company is reaffirming the guidance set forth in its February 12, 2026 press release.
- INSIDERSEC Form 4 filed by SVP, GC & Corporate Secretary Finch Norman D. Jr.4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO and Board Chair Green Eric Mark4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERSEC Form 4 filed by Sr. VP & Chief HR Officer Favorite Annette F4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERSEC Form 4 filed by SVP, Proprietary Segment Campbell Shane Alden4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERSEC Form 4 filed by SVP & Chief Financial Officer Mcmahon Robert W.4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERSEC Form 4 filed by SVP, Strategy & Corporate Dev Poussot Rodolphe Jean4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERSEC Form 4 filed by VP, Chief Accounting Officer Winters Chad4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- PRWest to Participate in Upcoming Investor ConferencesEXTON, Pa., Feb. 27, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Barclays Global Healthcare Conference: Fireside chat at 9:00 AM EDT on Tuesday, March 10, 2026KBCM Healthcare Forum: Fireside chat at 1:30 PM EDT on Wednesday, March 18, 2026The live webcasts for these events can be accessed in the Investors section of the Company's website. A replay of each webcast will also be available on the Com
- INSIDERSVP, Strategy & Corporate Dev Poussot Rodolphe Jean converted options into 383 shares and covered exercise/tax liability with 130 shares, increasing direct ownership by 83% to 561 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERVP & Treasurer Witherspoon Charles converted options into 60 shares and covered exercise/tax liability with 22 shares, increasing direct ownership by 3% to 1,408 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERVP, Chief Accounting Officer Winters Chad converted options into 89 shares and covered exercise/tax liability with 30 shares, increasing direct ownership by 4% to 1,523 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERSVP, Strategy & Corporate Dev Poussot Rodolphe Jean converted options into 82 shares and covered exercise/tax liability with 28 shares, increasing direct ownership by 22% to 307 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERVP & Treasurer Witherspoon Charles covered exercise/tax liability with 42 shares and was granted 116 shares, increasing direct ownership by 6% to 1,370 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERVP, Chief Accounting Officer Winters Chad was granted 150 shares and covered exercise/tax liability with 51 shares, increasing direct ownership by 7% to 1,462 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)